A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

Citi analyst Geoff Meacham initiated coverage of Biogen (BIIB) with a Neutral rating and $190 price target The company’s strategy to offset core franchise erosion has been to develop assets with ...

We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...